CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 100 enrolled
Drug / intervention
Rivaroxaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03702582
NCT03702582Phase 3Completed
CompareCT.gov

Trial of New Oral Anticoagulants vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation

Massachusetts General Hospital·interventional·Posted Oct 11, 2018·Updated May 19, 2026

In Brief

A Phase 3 clinical trial evaluating Rivaroxaban and Warfarin for Atrial Fibrillation and 2 related conditions. Completed, enrolled 100 participants across 1 site.

Detailed Summary

This prospective, randomized, active-controlled, parallel arm study compares the safety and financial benefits of arterial thromboembolism prophylaxis with Warfarin vs. Rivaroxaban (A novel oral anticoagulant) in patients with new onset atrial fibrillation after sternotomy for cardiac operations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Stroke, Bleeding
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedOct 11, 2018
Enrollment StartApr 30, 2019
Primary CompletionOct 1, 2023
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 7.7 years ago

Interventions

Rivaroxabandrug

Anticoagulant drug that works via direct inhibition of factor Xa. FDA approved for prophylaxis against stroke in non-valvular atrial fibrillation

Warfarindrug

Anticoagulation drug that works via inhibition of vitamin K dependent clotting factors. FDA approved for prophylaxis against stroke in atrial fibrillation